| Diclofenac Sodium | Horizon Pharma | ||
| 1.5% ; Topical solution |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| Indicated for the treatment of the pain of osteoarthritis of the knee | |||
|
Yes
| |||
| Pennsaid | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ***** | ******* | ******* | ******* | ******* | ******* | ||||||||||||||
| ****** | ******* | ******* | ******* | ******* | ******* | ||||||||||||||
| **** ****** | ******* | ******* | ******* | ******* |
| Diclofenac Sodium | Horizon Pharma | ||
| 2%; Topical Solution |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
More Than 5
|
||
| indicated for the pain of Osteoarthritis of the knee | |||
|
Yes
| |||
| Pennsaid | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | *** ** ** | ********* **** ** ** | **** ** ** | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | ********* **** ** ** | *** ** ** | *** ** ** | *** ** ** | *** ** ** | *** ** ** | *** ** ** |
| ******* | ******* | ******* | ******* | ******* | ******* | *** ********* | ******* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | *** **, **** | ******* | ********* ******** | ****** **** ******** |
| ******* | ** \ ** | *** **, **** | ******* | ********* ******** | ******* ******** ** ** ** *** **** |
| ***** | ** \ ** | *** **, **** | ******* | ******** | ******** ** ** ** *** **** |
Download ParaIV Report